Inhibition of ADP-Induced Platelet Aggregation and Fibrinogen Binding to IIBβ3 by Antagonists
| αIIbβ3 Antagonist . | Platelet Aggregation IC50 (nmol/L) . | Fibrinogen Binding IC50 (nmol/L) . |
|---|---|---|
| FR184764 | 19.6 ± 2.5 | 9.0 ± 2.1 |
| SC54701 | 19.3 ± 6.2 | 11.5 ± 5.3 |
| FR169824 | 33.7 ± 4.6 | 19.7 ± 4.5 |
| FK633 | 110.0 ± 28.6 | 39.3 ± 7.7 |
| Ro44-9883 | 20.3 ± 3.4 | 4.4 ± 0.4 |
| MK383 | 33.0 ± 10.8 | 6.1 ± 0.9 |
| RGDW | 17,333.3 ± 6,549.0 | ND |
| αIIbβ3 Antagonist . | Platelet Aggregation IC50 (nmol/L) . | Fibrinogen Binding IC50 (nmol/L) . |
|---|---|---|
| FR184764 | 19.6 ± 2.5 | 9.0 ± 2.1 |
| SC54701 | 19.3 ± 6.2 | 11.5 ± 5.3 |
| FR169824 | 33.7 ± 4.6 | 19.7 ± 4.5 |
| FK633 | 110.0 ± 28.6 | 39.3 ± 7.7 |
| Ro44-9883 | 20.3 ± 3.4 | 4.4 ± 0.4 |
| MK383 | 33.0 ± 10.8 | 6.1 ± 0.9 |
| RGDW | 17,333.3 ± 6,549.0 | ND |
Values are given as the mean ± SD (n = 3). Platelet aggregation and fibrinogen binding were performed by using 10 and 20 μmol/L ADP, respectively.
Abbreviation: ND, not determined.